13F filer · CIK 1422848 ↗
Capital Research Global Investors
You are looking at Q3 2018. See the latest, Q2 2026 →
Reported value
$344.02B
−6.0% on the quarter before
Positions
436
45 new · 49 sold out
Top 10
29.1%
of the value
Est. gain
+$15.86B
on stocks held all quarter
Est. return
+5.3%
on those stocks since Q2 2018
Positions as of Sep 30, 2018, from Capital Research Global Investors's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
The 24 largest positions, 47% of the reported value, each sized by its share, colored by what the fund did with it since Q2 2018. Striped tiles are options.
Largest buys
Since Q2 2018, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Meta~$4.14BAdded · 1.9% → 2.9%+25,147,288 shares
- Gilead Sciences Inc~$989.7MAdded · 1.1% → 1.6%+12,818,301 shares
- Cme Group Inc Cl A~$963.1MAdded · 0.2% → 0.5%+5,658,108 shares
- Broadcom~$890.3MAdded · 1.5% → 1.8%+3,608,395 shares
- Te Connectivity Ltd~$720.1MNew · 0.0% → 0.2%+8,189,669 shares
- MercadoLibre~$711.2MAdded · 0.0% → 0.3%+2,088,781 shares
- Cigna Corp~$682.2MNew · 0.0% → 0.2%+3,275,920 shares
- First Republic Bank~$675.1MNew · 0.0% → 0.2%+7,032,359 shares
- Visa Inc.~$659.7MAdded · 0.0% → 0.2%+4,395,051 shares
- Amphenol~$649.2MAdded · 0.1% → 0.3%+6,905,120 shares
Largest sells
Since Q2 2018, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Csx Corp~$2.52BCut · 1.3% → 0.9%−34,092,480 shares
- Wells Fargo And Co~$2.39BCut · 1.2% → 0.5%−45,463,282 shares
- Amgen Inc~$2.39BCut · 2.3% → 2.1%−11,515,778 shares
- Illumina Inc~$1.72BCut · 1.0% → 0.8%−4,692,864 shares
- Abbvie Inc~$1.67BCut · 4.9% → 4.8%−17,628,648 shares
- Netflix~$1.66BCut · 4.0% → 3.6%−4,445,531 shares
- Stryker Corp~$1.60BCut · 1.1% → 0.8%−9,014,729 shares
- Twenty-First Century Fox Inc Cl A (Limited Voting)~$1.60BCut · 0.7% → 0.2%−34,479,991 shares
- Amazon~$1.59BCut · 3.2% → 3.5%−795,005 shares
- Union Pacific Corp~$1.47BCut · 0.6% → 0.3%−9,026,337 shares
Holdings
As of Sep 30, 2018. Changes are in shares against Jun 30, 2018, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie IncCOMMON STOCK · shares −9.1% · price +2.1% | 4.8% | $16.66B | +$340.0M | ||||||||
| MicrosoftCOMMON STOCK · shares +5.5% · price +16.0% | 3.6% | $12.46B | +$1.63B | ||||||||
| NetflixCOMMON STOCK · shares −12% · price −4.4% | 3.6% | $12.41B | −$574.1M | ||||||||
| AmazonCOMMON STOCK · shares −12% · price +17.8% | 3.5% | $12.10B | +$1.83B | ||||||||
| MetaCOMMON STOCK · shares +72% · price −15.4% | 2.9% | $9.92B | −$1.05B | ||||||||
| Abbott LaboratoriesCOMMON STOCK · shares −4.5% · price +20.3% | 2.7% | $9.18B | +$1.55B | ||||||||
| AlphabetCOMMON STOCK · shares −0.3% · price +7.0% | 2.2% | $7.67B | +$500.4M | ||||||||
| Amgen IncCOMMON STOCK · shares −25% · price +12.3% | 2.1% | $7.14B | +$781.4M | ||||||||
| AlphabetCOMMON STOCK · shares +2.6% · price +6.9% | 1.9% | $6.40B | +$402.4M | ||||||||
| BroadcomCOMMON STOCK · shares +16% · price +1.7% | 1.8% | $6.34B | +$90.3M | ||||||||
| Eog Resources IncCOMMON STOCK · shares −15% · price +2.5% | 1.6% | $5.57B | +$137.2M | ||||||||
| Gilead Sciences IncCOMMON STOCK · shares +22% · price +9.0% | 1.6% | $5.39B | +$363.3M | ||||||||
| Verizon Communications IncCOMMON STOCK · shares −17% · price +6.1% | 1.5% | $5.31B | +$306.5M | ||||||||
| IntelCOMMON STOCK · shares −5.8% · price −4.9% | 1.5% | $5.10B | −$261.0M | ||||||||
| Unitedhealth Group IncCOMMON STOCK · shares −22% · price +8.4% | 1.5% | $5.07B | +$394.4M | ||||||||
| Nike Inc Cl BCOMMON STOCK · shares +0.7% · price +6.3% | 1.3% | $4.60B | +$272.1M | ||||||||
| Altria Group IncCOMMON STOCK · shares −8.4% · price +6.2% | 1.3% | $4.34B | +$253.0M | ||||||||
| MastercardCOMMON STOCK · shares +10% · price +13.3% | 1.3% | $4.33B | +$459.2M | ||||||||
| General Dynamics CorpCOMMON STOCK · shares −12% · price +9.8% | 1.2% | $4.24B | +$379.2M | ||||||||
| Exxon Mobil CorpCOMMON STOCK · shares −8.0% · price +2.8% | 1.2% | $4.23B | +$114.0M | ||||||||
| Thermo Fisher Scientific IncCOMMON STOCK · shares −15% · price +17.8% | 1.1% | $3.88B | +$587.1M | ||||||||
| Philip Morris InternationalCOMMON STOCK · shares +11% · price +1.0% | 1.1% | $3.78B | +$33.4M | ||||||||
| Lowes Companies IncCOMMON STOCK · shares −3.7% · price +20.1% | 1.1% | $3.64B | +$610.0M | ||||||||
| AlibabaCOMMON STOCK · shares +8.5% · price −11.2% | 1.0% | $3.53B | −$410.1M | ||||||||
| Home Depot IncCOMMON STOCK · shares −14% · price +6.2% | 1.0% | $3.53B | +$205.2M | ||||||||
| Total · 436 positions | 100% | $344.02B | +$15.86B |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q2 2018 to Q3 2018: 385 stocks held throughout, up $15.86B (+5.3%).
- Amazon+$1.83B+18%
- Microsoft+$1.63B+16%
- Abbott Laboratories+$1.55B+20%
- Amgen Inc+$781.4M+12%
- Qualcomm+$703.4M+28%
- Intel−$261.0M−5%
- Teva Pharmaceutical Industries Ltd ADR−$330.4M−11%
- Alibaba−$410.1M−11%
- Netflix−$574.1M−4%
- Meta−$1.05B−15%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 12, 2026 | $716.87B+11% | SEC ↗ |
| Q1 2026 | May 13, 2026 | $644.56B+19% | SEC ↗ |
| Q4 2025 | Feb 11, 2026 | $541.73B+2% | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | $532.97B+7% | SEC ↗ |
| Q2 2025 | Aug 13, 2025 | $499.46B+9% | SEC ↗ |
| Q1 2025 | May 12, 2025 | $459.90B−5% | SEC ↗ |
| Q4 2024 | Feb 13, 2025 | $486.38B+1% | SEC ↗ |
| Q3 2024 | Nov 13, 2024 | $481.14B+6% | SEC ↗ |
| Q2 2024 | Aug 13, 2024 | $455.74B+3% | SEC ↗ |
| Q1 2024 | May 14, 2024 | $441.98B+9% | SEC ↗ |
| Q4 2023 | Feb 13, 2024 | $406.47B+12% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $363.16B−3% | SEC ↗ |
| Q2 2023 | Aug 11, 2023 | $373.18B+7% | SEC ↗ |
| Q1 2023 | May 15, 2023 | $350.40B+6% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $330.88B+9% | SEC ↗ |
| Q3 2022 | Nov 14, 2022 | $304.37B−5% | SEC ↗ |
| Q2 2022 | Aug 15, 2022 | $321.05B−21% | SEC ↗ |
| Q1 2022 | May 19, 2022 (amended) | $405.10B−11% | SEC ↗ |
| Q4 2021 | Feb 14, 2022 | $452.67B+6% | SEC ↗ |
| Q3 2021 | Nov 15, 2021 | $428.65B−0% | SEC ↗ |
| Q2 2021 | Aug 16, 2021 | $429.52B+5% | SEC ↗ |
| Q1 2021 | May 14, 2021 | $408.71B+6% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $385.30B+16% | SEC ↗ |
| Q3 2020 | Nov 13, 2020 | $333.11B+5% | SEC ↗ |
| Q2 2020 | Aug 14, 2020 | $316.13B+24% | SEC ↗ |
| Q1 2020 | May 15, 2020 | $254.90B−24% | SEC ↗ |
| Q4 2019 | Feb 18, 2020 | $333.48B+9% | SEC ↗ |
| Q3 2019 | Nov 14, 2019 | $304.85B−3% | SEC ↗ |
| Q2 2019 | Aug 14, 2019 | $314.99B−0% | SEC ↗ |
| Q1 2019 | May 15, 2019 | $315.45B+10% | SEC ↗ |
| Q4 2018 | Feb 14, 2019 | $287.02B−17% | SEC ↗ |
| Q3 2018 | Nov 14, 2018 | $344.02B−6% | SEC ↗ |
| Q2 2018 | Aug 14, 2018 | $366.12B+4% | SEC ↗ |
| Q1 2018 | May 15, 2018 | $351.43B+3% | SEC ↗ |
| Q4 2017 | Feb 14, 2018 | $340.76B+3% | SEC ↗ |
| Q3 2017 | Nov 14, 2017 | $331.24B+4% | SEC ↗ |
| Q2 2017 | Aug 14, 2017 | $319.49B+1% | SEC ↗ |
| Q1 2017 | May 15, 2017 | $317.04B+3% | SEC ↗ |
| Q4 2016 | Feb 15, 2017 | $308.47B+2% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 | $302.53B+3% | SEC ↗ |
| Q2 2016 | Aug 15, 2016 | $292.47B+1% | SEC ↗ |
| Q1 2016 | May 16, 2016 | $290.06B | SEC ↗ |